Cytek Biosciences, Inc.
CTKB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001831915
No open-market purchases or sales by Cytek Biosciences, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $361.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Cytek Biosciences, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 129 | 1 | 136 | +8 |
| Shares | 76.2M | 17.1M | 75.0M | +15.8M (+26.8%) |
| Value | $425.1M | $95.3M | $415.3M | +$85.4M (+25.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Cytek Biosciences, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 18,492,291 | $102.4M | 0.00% |
| Jacobs Levy Equity Management, Inc | 182,713 | $1.01M | 0.00% |
| Jump Financial, LLC | 73,697 | $408.3K | 0.01% |
| Franklin Resources Inc | 76,117 | $404.9K | 0.00% |
| Public Employees Retirement System of Ohio | 48,520 | $268.8K | 0.00% |
| STRS Ohio | 26,200 | $145.1K | 0.00% |
| XTX Topco Ltd | 26,150 | $144.9K | 0.01% |
| Oxford Asset Management LLP | 25,257 | $139.9K | 0.12% |
| Intech Investment Management LLC | 23,137 | $128.2K | 0.00% |
| Keebeck Alpha, LP | 12,984 | $71.9K | 0.05% |
| Graham Capital Management, L.P. | 10,220 | $56.6K | 0.00% |
| Canada Pension Plan Investment Board | 2,400 | $13.3K | 0.00% |
| Versant Capital Management, Inc | 1,028 | $5.70K | 0.00% |
| US Bancorp | 1,000 | $5.54K | 0.00% |
| Sterling Capital Management LLC | 432 | $2.39K | 0.00% |
| Signaturefd, LLC | 113 | $626 | 0.00% |
| Quadrant Capital Group LLC | 99 | $549 | 0.00% |
| Allworth Financial LP | 98 | $543 | 0.00% |
| Mendota Financial Group, LLC | 13 | $73 | 0.00% |
| Capital Performance Advisors LLP | 12 | $66 | 0.00% |
Sold out (12)
Institutions that held Cytek Biosciences, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Natixis Advisors, L.P. | 35,951 | $201.0K |
| SG Americas Securities, LLC | 32,333 | $180.0K |
| Cornerstone Investment Partners, LLC | 23,554 | $131.4K |
| Versor Investments LP | 22,400 | $125.0K |
| Quadrature Capital Ltd | 21,229 | $118.2K |
| Dark Forest Capital Management LP | 21,098 | $117.7K |
| Balyasny Asset Management LLC | 16,238 | $90.6K |
| Cerity Partners LLC | 11,815 | $65.9K |
| Catalyst Funds Management Pty Ltd | 2,700 | $15.1K |
| Clear Street Markets LLC | 878 | $5.00K |
| EverSource Wealth Advisors, LLC | 158 | $1.06K |
| Huntington National Bank | 36 | $201 |
Not filed for Q3 2024 yet (1)
Institutions that held Cytek Biosciences, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 17,070,422 | $95.3M |